Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Abstract: The invention relates to a method for press hardening sheet steel components in which a blank is detached from a sheet steel band composed of a hardenable steel alloy and the blank is then austenitized, in that it is heated to a temperature greater than Ac3 and is then inserted into a forming tool and formed in the forming tool, and during the forming, is cooled at a speed greater than the critical hardening speed, characterized in that in order to inhibit microcracks of the second type from being produced during the forming and hardening process in the sheet metal blanks that are to be formed, oxygen is supplied adjacent to the positive radii and/or drawing edges; the invention also relates to a device for performing this method.

Abstract: The invention relates to an apparatus for heating sheet steel blanks, in particular for shaping and hardening in a press hardening process, wherein there is a heating device, and the heating device includes at least one heating module; the at least one heating module has a boxlike element embodied in cassette-like fashion, which has a plate-shaped or rectangular cavity that has a flat plate on an underside; at least one heating element is positioned in the cavity, which element is embodied as an electrical resistance heating element, and the cavity is completely filled in an embedding fashion so that it is completely enclosed by a highly heat-conductive material, preferably copper, and relates to a method therefor.

Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders. In certain embodiments, disclosed herein is an extended-release pharmaceutical formulation comprising, in a solid dosage form for oral delivery of between about 100 mg and about 1 g total weight: between about 2 and about 18% of an active ingredient; between about 70% and about 96% of one or more diluents; between about 1% and about 10% of a water-soluble binder and between about 0.5 and about 2% of a surfactant.

Abstract: A stator to guide a location-dependent magnetic field in a circumferential direction around a rotation axis. In one example, the stator includes a first stator ring revolving around the rotation axis, and a second stator ring revolving around the rotation axis and arranged concentrically with the first stator ring. The first and second stator rings include claws which are arranged so as to revolve around the rotation axis and at a distance from one another in the circumferential direction and engage with one another at least on a toothing axial plane. The claws are separated from one another by an air gap so that, when the magnetic field is arranged in the toothing axial plane, the magnetic field is guided towards the stator rings via the claws according to a relative angular position. Each claw has the contour of a mathematically smooth curve when viewed across the circumferential direction.

Abstract: A hygiene filter for a device for artificial respiration, having at least one filter for filtering microorganisms and/or solid particles from a respiratory air volume flow, and a device for artificial respiration, having a holding device within the air intake region. The filter material is designed as a sealing means against the respiratory air volume flow conducting elements such that the risk of the occurrence of secondary air is reduced.

Abstract: A method for producing a hardened steel component in which a sheet blank is stamped out and the stamped sheet blank is heated to a temperature ?Ac3 and as needed, is kept at this temperature for a predetermined time in order to carry out the austenite formation and then the sheet blank, which has been heated all over or only in some regions, is transferred to a forming die, is formed in the forming die, and in the forming die, is cooled at a speed that lies above the critical hardening speed and is thus hardened or else the sheet blank is completely cold formed and the formed sheet blank is heated all over or only in some regions to a temperature >Ac3 and as needed, is kept at this temperature for a predetermined time in order to carry out the austenite formation and then the sheet blank, which has been heated and formed all over or only in some regions, is transferred to a hardening die, and is hardened in the hardening die at a speed that lies above the critical hardening speed; the steel material is adj

Abstract: The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Abstract: A method for heating a blank or a preformed steel sheet component for hot forming and/or quench hardening purposes. In at least some regions, the heating is carried out to a temperature above AC3; the heating of the Hank is embodied as a rapid heating and to this end, the blank is heated in a first zone at an average heating rate of >25 K/s up to about 600° C. and above this temperature, is heated at an average heating rate of >10 K/s up to a maximum of the AC3 temperature and then is transferred to a second zone in which the blank that has been preheated in the first zone is heated in at least some regions to temperatures greater than AC3, in particular >850° C., with the heating rate in the second zone being >10 K/s. The invention also relates to a device for carrying out the method.

Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders. In certain embodiments, disclosed herein is an extended-release pharmaceutical formulation comprising, in a solid dosage form for oral delivery of between about 100 mg and about 1 g total weight: between about 2 and about 18% of an active ingredient; between about 70% and about 96% of one or more diluents; between about 1% and about 10% of a water-soluble binder and between about 0.5 and about 2% of a surfactant.

Abstract: A bearing arrangement for a steering shaft (10) of a vehicle, having a bearing plate (12) which has an inversion (18) and, at the bottom of the inversion, a bearing seat (14) in which a bearing (16) for the steering shaft (10) is held in such a way that a steering shaft (10) runs obliquely with respect to a plate plane (P) which is defined by the outer edge of the inversion (18), and having an insert (28) which is made from plastic, surrounds the steering shaft (10), and is fitted into the inversion (18), in which the inversion (18) has at least one section (24) with walls which run at right angles with respect to the plate plane (P), and the insert (28) has at least one disk (30, 32) which has a uniform thickness and is fitted into the cross-section of the section (24).

Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Abstract: The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.